Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is ≥100 Gy
BED
Biologically effective
Dose
NSCLC
SABR
Squamous cell carcinoma
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
24
05
2019
revised:
15
07
2019
accepted:
16
07
2019
entrez:
27
8
2019
pubmed:
27
8
2019
medline:
14
7
2020
Statut:
ppublish
Résumé
Squamous cell carcinoma (SCC) is associated with worse local control and overall survival (OS) compared to adenocarcinoma (ADC) in patients with early stage non-small cell lung cancer (ES-NSCLC). Biological effective dose (BED) escalation above 100 Gy We queried the National Cancer Database for ES-NSCLC (T1-2N0, Stage I-IIA) patients with SCC or ADC treated with stereotactic ablative radiotherapy (SABR). Receiver operator characteristic (ROC) curve analysis was used to identify the optimal dose threshold for SCC and ADC. Patients were stratified by histology and BED (≥122 Gy Ultimately 11,084 ES-NSCLC patients with either ADC (n = 6476) or SCC (n = 4608) were eligible for analysis. Calculated optimal BED threshold for both SCC and ADC was 122 Gy Escalation of BED ≥ 122 Gy
Identifiants
pubmed: 31446991
pii: S0169-5002(19)30556-2
doi: 10.1016/j.lungcan.2019.07.014
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-174Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.